SCHEDULE 13G: Armistice Capital Discloses 9.99% Passive Stake in BIO-key International Inc.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% passive ownership stake in BIO-key International Inc. through a Schedule 13G filing.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G with the SEC.
• The Reporting Persons beneficially own 596,401 shares of BIO KEY INTERNATIONAL INC. Common Stock, $0.0001 par value per share.
• This ownership represents 9.99% of the total outstanding shares of the class.
• The shares are held with shared voting power and shared dispositive power, both amounting to 596,401 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by an institutional investor like Armistice Capital is generally viewed positively as it signals confidence in the company's prospects, although the passive nature means no immediate strategic changes are implied.

Positives

• Armistice Capital, an investment manager, and Steven Boyd, its managing member, have taken a significant 9.99% stake in BIO KEY INTERNATIONAL INC., indicating confidence in the company's prospects.
• The investment is stated to be for ordinary course of business, suggesting a long-term, passive holding by a reputable institutional investor.

Negatives

• No specific negative information was disclosed in this Schedule 13G filing.

Risks

• The filing explicitly states that the securities were not acquired for the purpose of changing or influencing the control of the issuer, which means there is no indication of potential activist involvement or strategic changes driven by this new significant shareholder.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from Armistice Capital, LLC and Steven Boyd)

Industry Context

This filing indicates that a notable investment firm, Armistice Capital, sees value in BIO KEY INTERNATIONAL INC., a company likely operating in the biometrics or identity management sector, suggesting potential growth or undervaluation in this industry segment.

Stakeholder Impact

• Shareholders: May view the institutional investment as a positive signal, potentially increasing confidence and demand for the stock.
• Management: Could see this as validation of their current strategy, but also a new significant shareholder to consider in future communications.

Next Steps

• The Reporting Persons will be required to file amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., above 10% or below 5%) or if their investment intent changes from passive to active.

Key Dates

Recommendation

Keywords

BIO KEY INTERNATIONAL INC, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, biometrics, identity management